Esperion Therapeutics' Series B Round

Esperion Therapeutics raised a round of funding on April 25, 2013.

Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase i…

Articles about Esperion Therapeutics' Series B Round: